Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...
The approvals were based on positive results from EV-302, in which Padcev plus Keytruda resulted in statistically significant ...
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...
IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...
Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...
News Medical on MSN9h
Radiation plus combination immunotherapy may help preserve bladder in some patients with muscle-invasive bladder cancerPatients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ ...
Astellas Pharma has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare seeking ...
(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration approved expanded U.S. Prescribing information for IZERVAY (avacincaptad pegol intravitreal ...
US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback